Search results for "pituitary"

showing 10 items of 238 documents

The influence of personality on the effect of iTBS after being stressed on cortisol secretion

2019

Over the last years, individualization of repetitive Transcranial Magnetic Stimulation (rTMS) parameters has been a focus of attention in the field of non-invasive stimulation. It has been proposed that in stress-related disorders personality characteristics may influence the clinical outcome of rTMS. However, the underlying physiological mechanisms as to how personality may affect the rTMS response to stress remains to be clarified. In this sham-controlled crossover study, after being stressed by the Trier Social Stress Test, 38 healthy females received two sessions of intermittent theta burst stimulation (iTBS) applied to the left dorsolateral prefrontal cortex. To take possible personali…

MaleTRANSCRANIAL MAGNETIC STIMULATIONSALIVARY CORTISOLHydrocortisonePhysiologymedicine.medical_treatmentEmotionsIndividualitySocial SciencesHF-RTMS SESSIONPREFRONTAL CORTEXBiochemistryCortisol0302 clinical medicineMedicine and Health SciencesTrier social stress testPsychologyLipid Hormonesmedia_commonBrain MappingCross-Over StudiesMultidisciplinaryDepressionQRGeneral MedicineTranscranial Magnetic StimulationHealthy VolunteersElectrophysiologyBioassays and Physiological AnalysisBrain ElectrophysiologyMedicineFemaleGeneral Agricultural and Biological SciencesPsychologyResearch ArticlePersonalityClinical psychologyAdultCortisol secretionSEX-DIFFERENCESSciencePSYCHOSOCIAL STRESSmedia_common.quotation_subjectPsychological StressNeurophysiologyPrefrontal CortexGenetics and Molecular BiologyResearch and Analysis MethodsAffect (psychology)Young Adult03 medical and health sciencesMental Health and Psychiatry5-FACTOR MODELmedicineHumansPersonalityTranscranial StimulationSalivaSecretionPersonality TraitsSteroid HormonesMood DisordersUNDER-THE-CURVEElectrophysiological TechniquesCooperativenessBiology and Life SciencesMAJOR DEPRESSIONHormones030227 psychiatryTranscranial magnetic stimulationAffectMoodGeneral BiochemistryTemperament and Character InventoryPITUITARY-ADRENAL AXISPhysiological ProcessesStress Psychological030217 neurology & neurosurgeryNeuroscience
researchProduct

Treatment of pituitary resistance to thyroid hormone (PRTH) in an 8-year-old boy.

1996

We report on an 8-year-old boy with pituitary resistance to thyroid hormone (PRTH) having a cysteine for arginine substitution at codon 320 in the TR-beta gene who was presented because of thyrotoxicosis. Due to its suppressive effect on the pituitary thyrotropin secretion, treatment with D-thyroxine (D-T4) was started. After a few days, clinical euthyroidism was achieved but thyroid stimulating hormone secretion was not suppressed. Symptoms of thyrotoxicosis relapsed when therapy was interrupted so that therapy with D-T4 was reinstituted and continued to date. Symptoms did not recur, and the psychomotor development proceeded normally. D-T4 should therefore be considered in the treatment of…

MaleThyroid Hormone Resistance Syndromeendocrine systemmedicine.medical_specialtyPituitary glandendocrine system diseasesArginineTreatment outcomeMolecular Sequence DataPathogenesisInternal medicineMedicineHumansAmino Acid SequenceDextrothyroxineThyroid-stimulating hormone secretionChildbusiness.industryThyroidGeneral MedicineD-Thyroxinemedicine.anatomical_structureEndocrinologyThyrotoxicosisTreatment OutcomePediatrics Perinatology and Child HealthMutationbusinessHormoneActa paediatrica (Oslo, Norway : 1992)
researchProduct

Selective bilateral blood sampling from the inferior petrosal sinus in Cushing's disease: effects of corticotropin-releasing factor and thyrotropin-r…

1993

We sought to enhance the sensitivity of selective bilateral blood sampling to determine adrenocorticotropin (ACTH) and prolactin levels in the inferior petrosal sinus (IPS) by administering two stimulatory agents--corticotropin-releasing factor (CRF) and thyrotropin-releasing hormone (TRH). We then determined the ACTH and prolactin levels in the IPS of 10 patients with Cushing's disease. After peripheral administration of both CRF and TRH, ACTH levels were significantly higher on the tumor side in all patients. The prolactin level was significantly higher on the tumor side when CRF or TRH was used to stimulate pituitary secretion. Postsurgical immunohistochemistry studies revealed productio…

Maleendocrine systemPituitary glandmedicine.medical_specialtyCorticotropin-Releasing HormoneThyrotropin-releasing hormonePituitary neoplasmPetrosal Sinus SamplingSensitivity and SpecificityCushing syndromeAdrenocorticotropic HormonePituitary Gland AnteriorInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingPituitary NeoplasmsCushing SyndromeThyrotropin-Releasing Hormonebusiness.industryInferior petrosal sinusCushing's diseasemedicine.diseaseProlactinProlactinmedicine.anatomical_structureEndocrinologyFemaleCardiology and Cardiovascular Medicinebusinesshormones hormone substitutes and hormone antagonistsBlood samplingCardiovascular and interventional radiology
researchProduct

Neurochemistry of olivocochlear neurons in the hamster.

2009

The present study was conducted to characterize the superior olivary complex (SOC) of the lower brain stem in the pigmented Djungarian hamster Phodopus sungorus. Using Nissl-stained serial cryostat sections from fresh-frozen brains, we determined the borders of the SOC nuclei. We also identified olivocochlear (OC) neurons by retrograde neuronal tracing upon injection of Fluoro-Gold into the scala tympani. To evaluate the SOC as a putative source of neuronal nitric oxide synthase (nNOS), arginine-vasopressin (AVP), oxytocin (OT), vasoactive intestinal polypeptide (VIP), or pituitary adenylate cyclase-activating polypeptide (PACAP) that were all found in the cochlea, we conducted immunohistoc…

Maleendocrine systemmedicine.medical_specialtyHistologyAuditory PathwaysPhodopusStilbamidinesVasoactive intestinal peptideHamsterNitric Oxide Synthase Type IOlivary NucleusNitric OxideOxytocinEfferent Pathwayschemistry.chemical_compoundInternal medicineCricetinaeNitrergic NeuronsPonsotorhinolaryngologic diseasesmedicineAnimalsNeurotransmitterEcology Evolution Behavior and SystematicsbiologyStaining and LabelingOlivocochlear systembiology.organism_classificationRetrograde tracingImmunohistochemistryCochleaNeuronal tracingPhodopusArginine VasopressinEndocrinologynervous systemchemistrySuperior olivary complexPituitary Adenylate Cyclase-Activating Polypeptidesense organsAnatomyhormones hormone substitutes and hormone antagonistsBiotechnologyAnatomical record (Hoboken, N.J. : 2007)
researchProduct

Interplay between PACAP and NO in mouse ileum

2003

Abstract We investigated the possibility that pituitary adenylate cyclase activating peptide (PACAP) has a role in the control of contractility in the mouse ileum. PACAP-(1-27) produced tetrodotoxin (TTX)-insensitive, concentration-dependent reduction of the amplitude of the spontaneous contractions of longitudinal muscle up to their complete disappearance. This effect was inhibited by PACAP-(6-38), PACAP receptor antagonist, and by apamin, blocker of small-conductance Ca2+-activated K+-channels. Nω-nitro- l -arginine methyl ester (L-NAME), nitric oxide (NO) synthase inhibitor, reduced the PACAP-inhibitory response, and the joint application of apamin plus L-NAME produced additive effects. …

Maleendocrine systemmedicine.medical_specialtyMuscle RelaxationMouse ileumStimulationIn Vitro TechniquesApaminSettore BIO/09 - FisiologiaContractilityMiceCellular and Molecular Neurosciencechemistry.chemical_compoundSmooth muscleIleumInternal medicinemedicineAnimalsMyocyteNitric Oxide DonorsPharmacologyDose-Response Relationship DrugNeuropeptidesNitric oxideSmooth muscle contractionMice Inbred C57BLPituitary adenylate cyclase-activating peptideEndocrinologyApaminchemistryTetrodotoxinPituitary Adenylate Cyclase-Activating PolypeptideSodium nitroprussidePACAP (pituitary adenylate cyclase activating peptide)hormones hormone substitutes and hormone antagonistsmedicine.drugNeuropharmacology
researchProduct

Treatment of cryptorchidism with a potent analog of gonadotropin-releasing hormone.

1978

Pernasal therapy of cryptorchidism with D-Leu6-des-Gly10-gonadotropin-releasing hormone ethylamide (D-Leu6-des-Gly10-GnRH-EA), a potent, long-acting GnRH analog, was attempted. Eleven prepubertal cryptorchid boys received between 25 microgram once daily and 25 to 50 microgram twice daily for 5 to 12 weeks. Complete testicular descent was achieved in 4 of the 11 boys. GnRH tests (1.5 microgram/kg intravenously), conducted in six boys before treatment, after 4 weeks of treatment, and in 2 boys 3 months after treatment, did not reveal changes in gonadotropin secretion indicative of precocious puberty or of decreased hypophyseal sensitivity to GnRH. Antibodies to the GnRH analog or to GnRH coul…

Maleendocrine systemmedicine.medical_specialtyTime FactorsGonadotropin-releasing hormoneInternal medicineCryptorchidismMedicinePrecocious pubertyHumansChildbusiness.industryObstetrics and GynecologyInfantGnRH AnalogLuteinizing Hormonemedicine.diseaseGonadotropin secretionEndocrinologyReproductive MedicineChild PreschoolAntibody FormationOnce dailyFollicle Stimulating HormonebusinessPituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsAfter treatmentGonadotropinsHormoneFertility and sterility
researchProduct

Corneal thickness in children with growth hormone deficiency: The effect of GH treatment.

2014

Abstract OBJECTIVE: The eye represents a target site for GH action, although few data are available in patients with GH deficiency (GHD). Our aim was to evaluate central corneal thickness (CCT) and intraocular pressure (IOP) values in GHD children to assess the role played by GHD or GH treatment on these parameters. DESIGN: In 74 prepubertal GHD children (51M, 23F, aged 10.4±2.4years) we measured CCT and IOP before and after 12months of treatment. A baseline evaluation was also made in 50 healthy children matched for age, gender and body mass index. The study outcome considered CCT and IOP during treatment and their correlations with biochemical and auxological data. RESULTS: No difference …

Malegrowth hormone deficiencymedicine.medical_specialtyIntraocular pressurePediatricsgenetic structuresEndocrinology Diabetes and MetabolismGrowth hormone deficiencySettore MED/13 - EndocrinologiaCorneaEndocrinologyGH treatmentInternal medicineHumansMedicineIn patientCorneal thickneChildDwarfism PituitaryIntraocular PressureBaseline valuesHuman Growth Hormonegrowth hormone deficiency; Corneal thickness; GH treatmentbusiness.industryOrgan Sizemedicine.diseaseeye diseasesEndocrinologyTarget siteGh treatmentFemalesense organsbusinessBody mass indexGH Deficiency
researchProduct

MRI findings and genotype analysis in patients with childhood onset growth hormone deficiency--correlation with severity of hypopituitarism.

2007

Aim: To evaluate the relationship between pituitary size, PIT1 and PROP1 genotype, and the severity of childhood onset growth hormone deficiency (coGHD). Patients: Forty-four patients with coGHD (34 M; 9.7 ± 4.1 years): severe isolated (SI) GHD (n = 14); partial isolated (PI) GHD (n = 13); multiple pituitary hormone deficiencies (MPHD) (n=17). Results: Pituitary abnormalities were found in 7/14 patients with SIGHD (50%), 16/17 patients with MPHD (94.1%), and no patient with PIGHD. Mean pituitary height (PHT SDS) was significantly lower in MPHD than in SIGHD and PIGHD. Pituitary height SDS and pituitary volume (PV) SDS correlated with IGF-I SDS and stimulated GH peaks in the SIGHD and MPHD g…

Malemedicine.medical_specialtyAdolescentGenotypeEndocrinology Diabetes and MetabolismGenotype AnalysisHypopituitarismHypopituitarismGrowth hormone deficiencyCorrelationEndocrinologyInternal medicineAge Determination by SkeletonGenotypemedicineHumansIn patientAge of OnsetChildDwarfism PituitaryRetrospective StudiesHomeodomain Proteinsbusiness.industrymedicine.diseaseMagnetic Resonance ImagingBody HeightEndocrinologyChild PreschoolPituitary GlandPediatrics Perinatology and Child HealthPituitary hormonesDisease ProgressionFemalebusinessTranscription Factor Pit-1Mri findingsJournal of pediatric endocrinologymetabolism : JPEM
researchProduct

Combined therapy with insulin and growth hormone in 17 patients with type-1 diabetes and growth disorders.

2013

<b><i>Background/Aim:</i></b> Combined growth hormone (GH) and insulin therapy is rarely prescribed by pediatric endocrinologists. We investigated the attitude of Italian physicians to prescribing that therapy in the case of short stature and type-1 diabetes (T1DM). <b><i>Methods:</i></b> A questionnaire was sent and if a patient was identified, data on growth and diabetes management were collected. <b><i>Results:</i></b> Data from 42 centers (84%) were obtained. Of these, 29 centers reported that the use of combined therapy was usually avoided. A total of 17 patients were treated in 13 centers (GH was started before T1…

Malemedicine.medical_specialtyAdolescentGrowth hormone; Insulin therapy; GH deficiency; Type-1 diabetes; Turner syndromeTurner syndromeEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType-1 diabeteseducationDwarfismTYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSGrowth hormoneSettore MED/38 - Pediatria Generale E SpecialisticaEndocrinologyInsulin resistancePharmacotherapySurveys and QuestionnairesInternal medicineDiabetes mellitusgrowth hormone treatment; TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSTurner syndromemedicineHumansHypoglycemic AgentsInsulinChildDwarfism PituitaryGrowth hormoneGrowth DisordersGH deficiencyType 1 diabetesHuman Growth Hormonebusiness.industryInsulingrowth hormone treatmentmedicine.diseaseDiabetes Mellitus Type 1EndocrinologyChild PreschoolPediatrics Perinatology and Child HealthInsulin therapyDrug Therapy CombinationFemaleInsulin Resistancebusiness
researchProduct

High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement tr…

2014

PURPOSE: Although the correlation between vitamin D and growth hormone (GH)-insulin-like growth factor 1 (IGF1) axis is documented, as of date, few and conflicting studies have prospectively analyzed vitamin D before and after GH treatment. Our aim was to evaluate as to how the condition of GH deficiency (GHD) or GH treatment influences vitamin D in children. METHODS: Eighty Sicilian GHD children (M/F 58/22; mean age 10.3 years), grouped according to the season of evaluation in group A (June-September; 41 children) and group B (November-February; 39 children), were evaluated at baseline and after 12 months of GH treatment. RESULTS: Twenty-eight children (35 %) were vitamin D insufficient an…

Malemedicine.medical_specialtyAdolescentHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentComorbidityGrowth hormoneGrowth hormone deficiencySettore MED/13 - EndocrinologiaYoung AdultEndocrinologyHypovitaminosisInternal medicinemedicineVitamin D and neurologyPrevalenceHumansChildDwarfism Pituitaryvitamin D growth hormoneHigh prevalencebusiness.industryHuman Growth HormoneGrowth factorInfantmedicine.diseaseVitamin D DeficiencyEndocrinologyTreatment OutcomeChild PreschoolGh treatmentFemalebusinessGH Deficiency
researchProduct